Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway
文献类型：期刊论文
| 作者 | Xiao, Wenqin1; Xu, Zhijian2 ; Chang, Shuaikang1; Li, Bo2; Yu, Dandan1; Wu, Huiqun1; Xie, Yongsheng1; Wang, Yingcong1; Xie, Bingqian1; Sun, Xi1
|
| 刊名 | Cancer letters
 |
| 出版日期 | 2018-12-21 |
| 卷号 | 444页码:45-59 |
| ISSN号 | 1872-7980 |
| DOI | 10.1016/j.canlet.2018.12.014 |
| 文献子类 | Article |
| 英文摘要 | Rafoxanide is used in veterinary medicine for the treatment of fascioliasis. We previously repositioned the drug as the inhibitor of B-Raf V600E, but its anti-tumor effect in human cancer has never been reported. In this study, we investigated the effects of rafoxanide in multiple myeloma (MM) in vitro and in vivo. We found that rafoxanide inhibited cell proliferation and overcame the protective effect of the bone marrow (BM) microenvironment on MM cells. Rafoxanide induced cell apoptosis by reducing mitochondrial membrane potential (MMP) and regulating the caspase pathway, while having no apparent toxic effect on normal cells. Rafoxanide also inhibited DNA synthesis and caused cell cycle arrest by regulating the cdc25A-degradation pathway. In addition, rafoxanide enhanced the DNA damage response by up-regulating the expression of γ-H2AX, and suppressed activation of the p38 MAPK pathway by down-regulating p38 MAPK phosphorylation and Stat1 phosphorylation. Rafoxanide treatment inhibited tumor growth, with no significant side effects, in an MM mouse xenograft model. Combination of rafoxanide with bortezomib or lenalidomide significantly induced synergistic cytotoxicity in MM cells. Finally, rafoxanide had anti-proliferation effect on both wild type and B-Raf V600E mutated MM cells. And the weaker anti-MM activity of rafoxanide than vemurafenib may indicate other potential mechanisms besides targeting B-Raf V600E mutation. Collectively, our results provide a rationale for use of this drug in MM treatment. |
| 语种 | 英语 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/266596]  |
| 专题 | 药物发现与设计中心 |
| 通讯作者 | Shi, Jumei; Zhu, Weiliang |
| 作者单位 | 1.Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China; 2.CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China |
| 推荐引用方式 GB/T 7714 | Xiao, Wenqin,Xu, Zhijian,Chang, Shuaikang,et al. Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway[J]. Cancer letters,2018,444:45-59. |
| APA | Xiao, Wenqin.,Xu, Zhijian.,Chang, Shuaikang.,Li, Bo.,Yu, Dandan.,...&Zhu, Weiliang.(2018).Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway.Cancer letters,444,45-59. |
| MLA | Xiao, Wenqin,et al."Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway".Cancer letters 444(2018):45-59. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。